Gilead Sciences Inc.'s bid to win marketing approvals for Viread against hepatitis B virus in the U.S. and Europe could mean upside for the compound - which sold $154.9 million in the third quarter as an HIV therapy - that's been overlooked so far by Wall Street, and investors are due for a full look at the data from a pair of supporting trials early next month. (BioWorld Today) Read More
